A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927)

医学 肺癌 阶段(地层学) 置信区间 放射治疗 不利影响 随机对照试验 放射科 核医学 外科 内科学 古生物学 生物
作者
Gregory M.M. Videtic,Chen Hu,Anurag K. Singh,Joe Y. Chang,William Parker,Kenneth R. Olivier,Steven E. Schild,Ritsuko Komaki,James J. Urbanic,Hak Choy
出处
期刊:International Journal of Radiation Oncology Biology Physics [Elsevier BV]
卷期号:93 (4): 757-764 被引量:326
标识
DOI:10.1016/j.ijrobp.2015.07.2260
摘要

To compare 2 stereotactic body radiation therapy (SBRT) schedules for medically inoperable early-stage lung cancer to determine which produces the lowest rate of grade ≥3 protocol-specified adverse events (psAEs) at 1 year.Patients with biopsy-proven peripheral (≥2 cm from the central bronchial tree) T1 or T2, N0 (clinically node negative by positron emission tomography), M0 tumors were eligible. Patients were randomized to receive either 34 Gy in 1 fraction (arm 1) or 48 Gy in 4 consecutive daily fractions (arm 2). Rigorous central accreditation and quality assurance confirmed treatment per protocol guidelines. This study was designed to detect a psAEs rate >17% at a 10% significance level (1-sided) and 90% power. Secondary endpoints included rates of primary tumor control (PC), overall survival (OS), and disease-free survival (DFS) at 1 year. Designating the better of the 2 regimens was based on prespecified rules of psAEs and PC for each arm.Ninety-four patients were accrued between September 2009 and March 2011. The median follow-up time was 30.2 months. Of 84 analyzable patients, 39 were in arm 1 and 45 in arm 2. Patient and tumor characteristics were balanced between arms. Four (10.3%) patients on arm 1 (95% confidence interval [CI] 2.9%-24.2%) and 6 (13.3%) patients on arm 2 (95% CI 5.1%-26.8%) experienced psAEs. The 2-year OS rate was 61.3% (95% CI 44.2%-74.6%) for arm 1 patients and 77.7% (95% CI 62.5%-87.3%) for arm 2. The 2-year DFS was 56.4% (95% CI 39.6%-70.2%) for arm 1 and 71.1% (95% CI 55.5%-82.1%) for arm 2. The 1-year PC rate was 97.0% (95% CI 84.2%-99.9%) for arm 1 and 92.7% (95% CI 80.1%-98.5%) for arm 2.34 Gy in 1 fraction met the prespecified criteria and, of the 2 schedules, warrants further clinical research.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
Stroeve发布了新的文献求助10
2秒前
欧阳月空完成签到,获得积分10
2秒前
2秒前
星辰大海应助李小宁采纳,获得10
3秒前
段一帆发布了新的文献求助10
3秒前
冷艳的姿发布了新的文献求助10
3秒前
4秒前
FIN应助小小采纳,获得30
4秒前
领导范儿应助su采纳,获得10
5秒前
Candy发布了新的文献求助10
5秒前
Rondab应助xiaosu采纳,获得10
6秒前
CodeCraft应助LJJ采纳,获得10
7秒前
7秒前
SYLH应助科研通管家采纳,获得20
8秒前
所所应助科研通管家采纳,获得10
8秒前
科研通AI5应助科研通管家采纳,获得10
8秒前
张金蝶完成签到,获得积分10
8秒前
搜集达人应助科研通管家采纳,获得10
9秒前
CAOHOU应助科研通管家采纳,获得10
9秒前
丘比特应助科研通管家采纳,获得10
9秒前
CAOHOU应助科研通管家采纳,获得10
9秒前
赘婿应助科研通管家采纳,获得10
9秒前
量子星尘发布了新的文献求助30
9秒前
SYLH应助科研通管家采纳,获得20
9秒前
9秒前
9秒前
9秒前
CAOHOU应助科研通管家采纳,获得10
9秒前
Lyuhng+1完成签到 ,获得积分10
10秒前
大个应助十九岁的时差采纳,获得10
11秒前
14秒前
桃花落完成签到,获得积分10
17秒前
su发布了新的文献求助10
17秒前
思源应助汪汪采纳,获得10
17秒前
高兴的天蓝完成签到 ,获得积分10
18秒前
18秒前
19秒前
星星应助momo采纳,获得10
19秒前
20秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989334
求助须知:如何正确求助?哪些是违规求助? 3531428
关于积分的说明 11253936
捐赠科研通 3270119
什么是DOI,文献DOI怎么找? 1804887
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809173